Surgical Window Study of CM93 in Subjects With Recurrent Glioblastoma (rGBM)
NCT07927491, Phase 1, Not yet recruiting, NYU Langone Health
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Surgical Window Study of CM93 in Subjects With Recurrent Glioblastoma (rGBM) | ClinicalTrials.gov |
| NCT number | NCT07927491 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Phase 1 | ClinicalTrials.gov |
| Enrollment | 72 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | NYU Langone Health | ClinicalTrials.gov |
| Conditions | Recurrent Glioblastoma With EGFR Mutation | ClinicalTrials.gov |
| Interventions | CM93 | ClinicalTrials.gov |
| First posted | 2026-11-10 | ClinicalTrials.gov |
| Last updated | 2026-11-10 | ClinicalTrials.gov |
Registered outcomes 9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Part 1: Number of Dose-limiting toxicities (DLTs) observed | From the first study treatment until the 30-Day Post Drug Visit | ClinicalTrials.gov | |
| Primary | Part 2: Concentration of CM93 in non-enhancing areas of the tumor | Day of Surgery (up to 2 weeks) | ClinicalTrials.gov | |
| Secondary | Part 1: Area under the curve (AUC) | Baseline through end of Cycle 1 (each cycle is 28 days) | AUC measures the total systemic exposure to a drug over a period of time. | ClinicalTrials.gov |
| Secondary | Part 1: Maximum plasma concentration (Cmax) | Baseline through end of Cycle 1 (each cycle is 28 days) | Cmax Cmax is the highest measured drug concentration in the plasma or serum after a dose is administered | ClinicalTrials.gov |
| Secondary | Part 1: Trough plasma concentration (Cmin) | Baseline through end of Cycle 1 (each cycle is 28 days) | Cmin is the lowest or minimum concentration a drug reaches in the plasma. | ClinicalTrials.gov |
| Secondary | Part 1: Time to maximum plasma concentration (Tmax) | Baseline through end of Cycle 1 (each cycle is 28 days) | Tmax is the time elapsed from administration until Cmax is reached. | ClinicalTrials.gov |
| Secondary | Part 1: Plasma half-life (T1/2) | Baseline through end of Cycle 1 (each cycle is 28 days) | T1/2 is the time required for the concentration of a drug in the plasma to decrease by 50%. | ClinicalTrials.gov |
| Secondary | Part 2: Concentration of CM93 in enhancing areas of the tumor | Day of Surgery (up to 2 weeks) | ClinicalTrials.gov | |
| Secondary | Part 2: Inhibition of epidermal growth factor receptor (EGFR) as determined by Phosphorylated Epidermal Growth Factor Receptor (p-EGFR) levels | Day of Surgery (up to 2 weeks) | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)